PA
DGX icon

Procyon Advisors’s Quest Diagnostics DGX Stock Holding History

Procyon Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$539K Buy
2,542
+5
+0.2% +$981 0.02% 349
2026
Q1 		$497K Buy
+2,537
New +$493K 0.02% 352
2025
Q2 		– Sell
-2,488
Closed -$421K – 505
2025
Q1 		$421K Buy
+2,488
New +$409K 0.03% 410
2020
Q3 		– Sell
-271
Closed -$31K – 395
2020
Q2 		$31K Buy
271
+29
+12% +$3.08K 0.02% 463
2020
Q1 		$19K Sell
242
-28
-10% -$2.9K 0.01% 491
2019
Q4 		$29K Buy
+270
New +$28.2K 0.02% 433

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Procyon Advisors's DGX Position: Q2 2026 in Review

Procyon Advisors increased its Quest Diagnostics (DGX) stake by 0.2% in Q2 2026, buying an estimated $981 and bringing the position to 2,542 shares worth $539K. The position accounts for 0.02% of the portfolio, ranked #349.

Procyon Advisors first reported a position in DGX in Q4 2019 and has held it in 6 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Procyon Advisors held 2,542 shares of Quest Diagnostics worth $539K as of Q2 2026.
  • Procyon Advisors bought 5 Quest Diagnostics shares in Q2 2026, an estimated $981.
  • Quest Diagnostics made up 0.02% of Procyon Advisors's portfolio in Q2 2026, its #349 holding.
  • Procyon Advisors first reported a position in Quest Diagnostics in Q4 2019 and has held it in 6 quarters since.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Procyon Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.